{"title":"Interspecies differences in plasma protein binding of beta-lactam antibiotics","authors":"Hifza Ahmed , Christoph Dorn , Markus Zeitlinger","doi":"10.1016/j.ijantimicag.2025.107476","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Plasma protein binding (PPB) is a critical factor in drug therapy and understanding free compound exposure across preclinical and clinical species is vital for developing new antibiotics. Optimising beta-lactam dosing based on unbound drug concentrations has garnered significant interest, yet there are few data on how interspecies differences in protein binding affect the attainment of targeted unbound concentrations.</div></div><div><h3>Methods</h3><div>The aim of this study was to examine the protein binding of three beta-lactams, cefiderocol, ceftriaxone, and temocillin, using human, bovine, and rat plasma. Total and unbound beta-lactam concentrations were measured using ultrafiltration. An interspecies comparison of PPB was conducted to evaluate variability in protein binding across the different species.</div></div><div><h3>Results</h3><div>The study data showed that PPB was highest in human plasma for all three beta-lactam antibiotics tested. PPB for cefiderocol and ceftriaxone was higher in rat plasma than in bovine plasma, whereas PPB for temocillin was higher in bovine plasma than in rat plasma.</div></div><div><h3>Conclusion</h3><div>The study highlights substantial interspecies differences in the PPB of cefiderocol, ceftriaxone, and temocillin. The findings indicate the need for careful consideration of species-specific PPB in the optimisation of beta-lactam dosing and the development of new pharmaceuticals.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"65 5","pages":"Article 107476"},"PeriodicalIF":4.9000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Antimicrobial Agents","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924857925000305","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Plasma protein binding (PPB) is a critical factor in drug therapy and understanding free compound exposure across preclinical and clinical species is vital for developing new antibiotics. Optimising beta-lactam dosing based on unbound drug concentrations has garnered significant interest, yet there are few data on how interspecies differences in protein binding affect the attainment of targeted unbound concentrations.
Methods
The aim of this study was to examine the protein binding of three beta-lactams, cefiderocol, ceftriaxone, and temocillin, using human, bovine, and rat plasma. Total and unbound beta-lactam concentrations were measured using ultrafiltration. An interspecies comparison of PPB was conducted to evaluate variability in protein binding across the different species.
Results
The study data showed that PPB was highest in human plasma for all three beta-lactam antibiotics tested. PPB for cefiderocol and ceftriaxone was higher in rat plasma than in bovine plasma, whereas PPB for temocillin was higher in bovine plasma than in rat plasma.
Conclusion
The study highlights substantial interspecies differences in the PPB of cefiderocol, ceftriaxone, and temocillin. The findings indicate the need for careful consideration of species-specific PPB in the optimisation of beta-lactam dosing and the development of new pharmaceuticals.
期刊介绍:
The International Journal of Antimicrobial Agents is a peer-reviewed publication offering comprehensive and current reference information on the physical, pharmacological, in vitro, and clinical properties of individual antimicrobial agents, covering antiviral, antiparasitic, antibacterial, and antifungal agents. The journal not only communicates new trends and developments through authoritative review articles but also addresses the critical issue of antimicrobial resistance, both in hospital and community settings. Published content includes solicited reviews by leading experts and high-quality original research papers in the specified fields.